key: cord-0431200-c11hjwv9
authors: Jakwerth, C. A.; Feuerherd, M.; Guerth, F. M.; Oelsner, M.; Schellhammer, L.; Giglberger, J.; Pechtold, L.; Jerin, C.; Kugler, L.; Mogler, C.; Haller, B.; Erb, A.; Wollenberg, B.; Spinner, C. D.; Buch, T.; Protzer, U.; Schmidt-Weber, C. B.; Zissler, U. M.; Chaker, A. M.
title: Early Reduction of SARS-CoV-2 Replication in Bronchial Epithelium by Kinin B2 Receptor Antagonism
date: 2021-08-18
journal: nan
DOI: 10.1101/2021.08.13.21262037
sha: fdfd404b4f5360971a618b84565778d7a4892413
doc_id: 431200
cord_uid: c11hjwv9

Background: SARS-CoV2 has evolved to enter the host via the ACE2 receptor which is part of the Kinin-kallirein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV2 infection and epithelial mechanisms of the kinin-kallikrein system at the kinin B2 receptor level in SARS-CoV-2 infection that is of direct translational relevance. Methods: From acute SARS-CoV-2-positive patients and -negative controls, transcriptomes of nasal brushings were analyzed. Primary airway epithelial cells (NHBEs) were infected with SARS-CoV-2 and treated with the approved B2R antagonist icatibant. SARS-CoV-2 RNA RT-qPCR, cytotoxicity assays, plaque assays and transcriptome analyses were performed. The treatment effect was further studied in a murine airway inflammation model in vivo. Results: Here, we report a broad and strong upregulation of kallikreins and the kinin B2 receptor (B2R) in the nasal mucosa of acutely symptomatic SARS-CoV-2-positive patients. A B2R antagonist impeded SARS-CoV-2 replication and spread in NHBEs, as determined in plaque assays on Vero E6 cells. B2R antagonism reduced the expression of SARS-CoV-2 entry receptor ACE2 in vitro and in a murine airway inflammation model in vivo. In addition, it suppressed gene expression broadly, particularly genes involved in G-protein-coupled-receptor signaling and ion transport. Conclusions: In summary, this study provides evidence that treatment with B2R antagonists protects airway epithelial cells from SARS-CoV-2 by inhibiting its replication and spread, through the reduction of ACE2 levels and the interference with several cellular signaling processes. Future clinical studies need to shed light on the airway protection potential of approved B2R antagonists, like icatibant, in the treatment of early-stage COVID-19.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 cleaves the coronaviral spike protein and primes it for cell fusion, while ACE2 enables the virus 141 particle to enter the cell by binding of its spike protein. 11, 12 The latter acts as central component 142 in its function as terminal carboxypeptidase in the counter-regulatory axis of the renin-143 angiotensin system (RAS) and the contact activation system (CAS), 10,13 which initiates blood 144 coagulation and can additionally activate the kinin-kallikrein system (KKS). 14 In its role in the 145 RAS, ACE2 has anti-vasoconstrictive and anti-inflammatory effects by hydrolyzing the 146 vasoconstrictive and tissue-damaging angiotensin II, which contributes to airway remodeling 147 and fibrosis, 15,16 to angiotensin (1-7). 17 In its role in the KKS, ACE2 further hydrolyzes 148 vasoactive peptides such as des-Arg9-bradykinin (DABK), which activates the inflammatory 149 axis of the KKS. 18, 19 While DABK is the ligand of the inducible kinin B1 receptor (BDKRB1; 150 B1 receptor), 20 bradykinin, the end product of the KKS cascade, binds to the constitutively 151 expressed kinin B2 receptor (BDKRB2; B2 receptor; B2R) and activates it. 21 Bradykinin 152 mediates its pro-inflammatory effects via the B2 receptor, by eliciting a variety of responses, 153

including vasodilation and edema, via the G protein-triggered phosphatidylinositol-calcium 154 second messenger system. 22-26 155 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 The fact that SARS-CoV-2 utilizes ACE2 to enter airway cells along with the fact that ACE2 156 is a multifunctional enzyme that counter-regulates the ACE-driven mechanisms of the RAS and 157 balances the KKS, may therefore explain the serious course of COVID-19, not only in the lungs 158 but systemically. 27,28 159 Recent publications suggest that the KKS could play a role in COVID-19. KKS comes into play 160 particularly in connection with the high prevalence of thromboembolic events in seriously ill 161 18, 20, 29, 30 A recent study on a cohort of 66 COVID-19 patients admitted to 162 the intensive care unit showed that the KKS was strongly activated, which was reflected in the 163 consumption of factor XII, pre-kallikrein and high-molecular-weight kininogen . 29 It has further been hypothesized that kinin-dependent "local lung angioedema" 165 involving the kinin B1 and B2 receptors is an important characteristic of This study examines the potential of interfering with the KKS at the kinin receptor level in 167 SARS-CoV-2 infection with translational relevance. Based on a broad and strong upregulation 168 of kallikreins and of the kinin B2 receptor in the nasal mucosa of acutely SARS-CoV-2-positive 169 patients, we hypothesized that the B2 receptor antagonism using icatibant, an approved 170 compound for the treatment of hereditary angioedema, 35 had an early protective effect against 171 SARS-CoV-2-mediated epithelial damage through disruption of ACE2-mediated virus entry. 172 173 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

The nasal brushings were performed as a part of a larger health professional observational 176 cohort study, which was approved by the ethics commission of the Technical University of 177

Munich (AZ 175/20s). Nasal brushings were subjected to whole-genome microarray 178 transcriptome analysis (see Supp.Info.). All patients gave written, informed consent prior to 179 participation (see Table 1 ). 180 181

Mice received murine IL-12Fc (1 μg of protein in 50 μL PBS) or PBS control intranasally. 36 183

Intranasal application was performed under isoflurane anesthesia in two steps of 25 μL per 184 nostril. 48 hours later, the mice received a single subcutaneous injection of icatibant (2 nmol 185 per 10 g body weight; HOE-140 (icatibant), H157, SLBX4410, Sigma) or PBS control. The 186 experiment was terminated by CO2 asphyxiation 6 hours or 24 hours after the injection of 187 icatibant. The experiment was carried out twice Organs were snap frozen for protein extraction. 188

Mice enrolled in the experiment were 6-8 weeks old, from either C57BL/6J, BALB/c or C3H 189

HeN strains. Both sexes were included for each strain and means of each mouse type (strain / 190 sex) are depicted as single values in Fig Animal Service Center of the University of Zurich in Schlieren (Schlieren, Zurich, 195 Switzerland). The animal vivarium was a specific-pathogen-free (SPF) holding room, that was 196 temperature-and humidity-controlled (21 ± 3 °C, 50 ± 10%), with a 12h light/dark cycle. All 197 animals had ad libitum access to the same food and water throughout the entire study. All 198 procedures described in this study had previously been approved by the Cantonal Veterinarian's 199 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Office of Zurich, Switzerland (License ZH096/20), and every effort was made to minimize the 200 number of animals used and their suffering. Experiments were pre-registered at 201 www.animalstudyregistry.org (study title "Effect of drug on ACE2 levels in mice"; 202 doi=10.17590/asr.0000225). 203

Detailed methods are provided in the online supporting information. 204 205 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 3 RESULTS 206

The enzyme ACE2 is the central viral entry receptor for the novel SARS-CoV-2 coronavirus 208 on human epithelial cells of the respiratory tract. 10 Recent studies showed that this receptor and 209 its co-receptors are not only expressed in the lower respiratory tract, and thus on the alveolar 210 epithelial cells type I and II, but are also present in the upper respiratory tract, but are 211 predominantly expressed in the nasal mucosa. 37 212

To investigate the local effect of the acute SARS-CoV-2 infection on the nasal epithelium, we 213 analyzed the transcriptome of nasal brushings from symptomatic patients who tested acutely 214 positive for SARS-CoV-2 and of SARS-CoV-2-negative patients. In a transcriptome analysis, 215 the most strongly induced genes encoding secreted factors included many members of the 216 kallikrein family (Fig.1A , Table S1 ). In particular, the kallikreins KLK5, KLK9 and KLK12 217 were significantly upregulated in acute SARS-CoV-2-positive patients compared to SARS-218

CoV-2-negative patients (Fig.1B , Table S2 ). A subsequent analysis focusing on central factors 219 of the KKS revealed that in addition, the kinin receptor B2 (BDKRB2; B2R) was also 220 significantly increased (Fig.1C , Table S3 ). This first finding, together with our hypothesis that 221 ACE2, as a central component, is counter-regulated by intervention in the KKS, prompted us 222 to investigate selective kinin B2 receptor antagonism in connection with SARS-CoV-2 223 infection. To circumvent the limitations of cell lines like Vero E6, A549 or Calu-3 cells that are 224 intrinsically impaired to form an interferon response upon viral infection, 38 we next infected 225 primary bronchial epithelial (NHBE) cells with SARS-CoV-2. 226

To examine the effects of SARS-CoV-2 infection and B2R antagonist treatment on the 227 microscopic integrity of the airway epithelium, 3D-air-liquid interphase organoid cultures were 228 differentiated from primary NHBEs (see Supp.Info). After complete differentiation, the 229 epithelia were pre-treated from the basal (medium) side with the approved B2R antagonist 230 icatibant, and subsequently infected with SARS-CoV-2 from the apical (air) side. The cultures 231 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 pre-treated with the B2R antagonist showed less virus-induced balloon-like structures compared 232 to untreated cultures. The epithelial layers remained qualitatively more intact, which indicated 233 a protective effect of the B2R antagonist for the bronchial epithelium (Fig.1D ). This finding 234 was further strengthened by cytotoxicity assays: The B2R antagonist had no toxic effects on 235

NHBEs even at high doses determined by lactate dehydrogenase (LDH) release, but rather 236 exhibited a cell-protecting effect in uninfected cells (Fig.1E ) as well as during SARS-CoV-2 237 infection (Fig.1F ). Next, the supernatants of pre-treated, infected primary NHBEs were 238 collected, titrated onto fresh Vero E6 cell cultures and plaque assays were performed. 239

Strikingly, we found that in vitro treatment of NHBEs with the B2R antagonist prior to infection 240 reduced the number of plaque forming units (PFU) in a plaque assay by 87% (Fig.1G) . In 241 addition, the levels of total SARS-CoV-2 RNA in cells that had been pretreated with the B2R 242 antagonist decreased by 52% compared to untreated infected NHBEs (Fig.1H ). With regard to 243 the virus entry process, ACE2 was reduced by pretreatment with the B2R antagonist on the 244 mRNA level (Fig. 1I) and on the protein level (Fig. 1J ). The membrane-standing protease 245 TMPRSS2 cleaves the spike protein for SARS-CoV-2 and primes it therefore for optimized 246 binding to its entry receptor ACE2. In contrast to ACE2, the TMPRSS2 transcript levels were 247 significantly increased in infected compared to uninfected NHBEs but were not affected by 248 The finding that B2R antagonism leads to a downregulation of ACE2 protein levels in lung 256 epithelial cells was confirmed in vivo in a murine airway inflammation model. 24 sex-matched 257 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101/2021.08.13.21262037 doi: medRxiv preprint mice from three different strains per group were treated in two blocks intranasally with murine 258 IL-12Fc to mimic virus-induced airway inflammation via activation of the IL-12 / IFN-g axis. 36 259

After 48 hours, mice were injected subcutaneously (s.c.) with the B2R antagonist and the 260 experiment was terminated six hours or 24 hours later. IL-12Fc-pretreated mice, which were 261 then further treated with the B2R antagonist on day 2, had significantly reduced ACE2 protein 262 levels in the lungs after six hours compared to control mice, which were only treated with PBS 263 on day 2 ( Fig.2A) . This effect decreased after 24 hours. 264

Anticipating treatment of SARS-CoV-2 infected patients with the B2R antagonist icatibant, 265

NHBEs were first infected with SARS-CoV-2 and then treated with the B2R antagonist six 266 hours after infection. Confirming the results of the pre-treatment, post-infection treatment with 267 the B2R antagonist also attenuated the cytopathic effect of SARS-CoV-2 ( Fig.2B ) and reduced 268 the number of PFU in a plaque assay on Vero E6 cells by 84% (Fig.2C) . 269

We also aimed to reflect pharmacokinetics 39 during treatment of early infection by treating CoV-2 N gene that is present in the viral genome and also in every SARS-CoV-2 protein-282 encoding transcript. The reduction in total SARS-CoV-2 RNA and genomic viral RNA during 283 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Table S6 ). In particular, 300 SARS-CoV-2 infection induced the antiviral cytidine deaminases APOBEC3A and B, which 301

we previously described to be induced by type-I interferons in the treatment of hepatitis-B virus 302

infection. 49 On the other hand, APOBEC3C mRNA levels were decreased in SARS-CoV-2-303 infected NHBE, which could indicate a novel evasion mechanism. 50 Neither the B2R antagonist 304 nor hydrocortisone inhibited the expression of genes with cell-intrinsic antiviral effects and 305 even increased the antiviral factor APOBEC3A at the mRNA level (Fig.3B , Table S7 ). 51 306

Our gene expression analysis data show that SARS-CoV-2 infection also induces the expression 307 of acute-phase proteins, such as TNF-a and IL-8 (CXCL8), 52,53 as well as IL-17C, MIP-308 3a (CCL20), IL-36g 54,55 and the chemokines CXCL1, -2, -3, -8, -17, CCL2, -3, -5 54 in primary 309 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101/2021.08.13.21262037 doi: medRxiv preprint lung epithelial cells (Fig.3C , Table S8 Table S8 ). Neither drug 315 interfered with canonical cellular antiviral -and reaction-triggering response mechanisms, 316

showing great potential for treatment options of COVID-19 while maintaining the host's 317 antiviral immune response. 318

In addition, we found that SARS-CoV-2 infection increases the expression of three known and 319 postulated entry (co-)receptors: 1) the transmembrane serine protease TMPRSS11A (Fig.S1C , 320

Tables S6,9-13), which was described to prime the MERS coronavirus spike protein 57 , 2) the 321 transmembrane serine protease TMPRSS11D, which was shown to activate SARS-CoV-2 spike 322 protein 58 and 3) the pathogen-associated molecular pattern-binding C-type lectin receptor DC-323 SIGN (CD209), which was described to serve as entry receptor for SARS-CoV 59 and has been 324 suggested to act as a receptor also for SARS-CoV-2. The induction of these additional entry 325 receptor candidates triggered by SARS-CoV-2 infection may potentiate the viral spread in the 326 bronchial epithelium and thus represent a pathogenetic approach that needs further research. 327

Overall, treatment with the B2R antagonist and hydrocortisone had no significant effects on the 328 expression of these candidate viral entry receptors (Fig.3D , Table S14 ). On the other hand, 329 hydrocortisone enhanced the expression of TMPRSS proteases (Fig.3D ). In particular, when 330 focusing on the known SARS-CoV-2 entry receptors, hydrocortisone treatment of uninfected 331 cells was already sufficient to induce an increase in TMPRSS2 gene expression (Fig.3E ). SARS-332

CoV-2 infection per se also increased TMPRSS2 expression, and pre-treatment of SARS-CoV-333 2-infected NHBEs with hydrocortisone further potentiated this effect. On the other hand, ACE2 334 expression showed only a slight upward trend after hydrocortisone pretreatment (Fig.S2B) . 335 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101/2021.08.13.21262037 doi: medRxiv preprint Finally, the hydrocortisone pre-treatment of SARS-CoV-2-infected NHBEs had no inhibitory 336 effect on the release of infectious particles 24 hours after infection (Fig.3F) , which was 337 expected since the treatment of COVID-19 patients with corticosteroids has an 338 immunomodulatory rationale. 339 340

With regard to the genes that are attenuated at the mRNA level by B2R antagonism, the DEGs 343 were analyzed in a network analysis using the database string to identify enriched cellular 344 processes. B2R antagonism reduced the expression levels of 343 membrane-bound receptors 345 significantly in treated versus untreated SARS-CoV-2-infected NHBEs (Table S15) perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101/2021.08.13.21262037 doi: medRxiv preprint

In this study, we provide evidence for the effect of interference with the KKS at the kinin B2 356 receptor level as a means of protecting the airway epithelium from SARS-CoV-2 infection, 357

while maintaining canonical cell-intrinsic antiviral response. 358

We initially hypothesized that through KKS interference, either feedback mechanisms or 359 modulated signal transduction target the virus entry receptor ACE2 and thus interfere with the 360 spread of SARS-CoV-2. To this end, the approved B2R antagonist icatibant was used in this 361 study. Here, we demonstrate that treatment with a B2R antagonist inhibits the replication and 362 spread of SARS-CoV-2 in primary airway epithelial cells, which was determined by a decrease 363 in total and genomic SARS-CoV-2 RNA, resulting in less infectious particles in plaque assays, 364 both when applied pre-and post-infection. While a low concentration of 1 nM B2R antagonist 365 was sufficient to reduce viral RNA in primary bronchial epithelial cells when cells were treated 366 pre-infection, 100 nM B2R antagonist was required to this effect, when cells were treated post-367

infection. In addition, the significant reduction in virus load as determined by PCR tapered off 368 after 96 hours. On the one hand, in vitro infections are performed with excess amounts of virus 369 particles. On the other hand, the fact that, due to its constitution as a peptide analog, the B2R 370 antagonist icatibant used in this study has a short half-life in the human body 39 but also 371 pharmacological tolerance to interference at receptor level may explain why the effect reached 372 significance after six hours but did not persist. Therefore, a higher dose of the B2R antagonist 373 may be required at even shorter repetitive dosing intervals to inhibit virus replication in the long 374 term. Therapeutic application in future dose finding studies should therefore focus on early 375 intervention with at least two doses daily 60 and on either optimized pharmacokinetics or 376 increased high local tissue concentrations, e.g. through topical application. 377 378 Two potential mechanisms of action for suppressing SARS-CoV-2 replication and spread in 379 airway epithelium are revealed by the current study: 380 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101/2021.08.13.21262037 doi: medRxiv preprint 1) Treatment with the B2R antagonist led to a downregulation of the viral entry receptor ACE2, 381 in vitro in primary airway epithelial cells and in vivo in a murine airway inflammation model. 382

Since the decrease of genomic SARS-CoV-2 RNA and total SARS-CoV-2 RNA was 383 comparable, we conclude that the B2R antagonist icatibant does probably not affect the viral 384 transcription machinery but inhibits the infection rather on the levels of entry, protein 385 synthesis/processing and assembly, maturation or budding. 386

In comparison, the corticosteroid hydrocortisone even upregulated TMPRSS2 in infected 387 airway epithelial cells. It is noteworthy that hydrocortisone did not change the release of 388 infectious particles from infected airway epithelial cells into the supernatant. Although 389 TMPRSS2 expression was even enhanced by hydrocortisone, our data implicate that this effect 390 on TMPRSS2 alone is insufficient to increase susceptibility for SARS-CoV-2 infection. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 We therefore conclude that B2R antagonism not only impedes the viral entry process by 406 reducing ACE2, as we had hypothesized, but also counter-regulates cellular processes that 407 include GPCR signaling and transmembrane ion transport, which SARS-CoV-2 may utilize for 408 efficient replication and viral spread. 409

In conclusion, the results of this study suggest that B2 receptor-antagonism protects airway 411 epithelial cells from SARS-CoV-2 spread by reducing ACE2 levels and by interfering with 412 several cellular signaling processes. Further research is needed to elucidate more details about 413 molecular mechanisms involved in the viral life cycle that kinin B2 receptor antagonism targets 414 and underlie its effects against SARS-CoV-2 infection. Based on these data, we speculate that 415 the protective effects of B2R antagonism could potentially prevent the early stages of COVID-416 19 from progressing into severe acute respiratory distress syndrome (ARDS) with structural 417 airway damage and fibrotic changes. We therefore propose that the safe approved B2R 418 antagonist icatibant be tested in clinical trials for two important aspects: 1) Treatment of early 419 COVID-19 disease targeting the replication and spread of the virus. 2) Optimized dosage 420 regimen to reflect pharmacokinetics and possible pharmacological tolerance at the receptor 421 level. Future controlled clinical trials must provide substantial evidence for optimal dosage 422 regimen, application, efficacy, and safety to investigate, whether KKS interference at the kinin 423 B2 receptor level can prevent the escalation of COVID-19 to ARDS and long-term lung damage. 424 425 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101/2021.08.13.21262037 doi: medRxiv preprint from 10 donors that were pre-treated with/without 1 nM B2R antagonist for 24 hours. 612

Supernatants were titrated on Vero E6 cells and plaque assay was quantified 24 hours later. 613 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Results are depicted as plaque forming units (PFU) per milliliter. 614 H) qPCR analysis of total SARS-CoV-2 RNA (viral genome and transcripts, which all contain 615 the N1 sequence region) normalized to human ACTB of SARS-CoV-2-infected primary NHBE 616 after 24 hours of pre-treatment with/without 1 nM B2R antagonist followed by 24 hours of 617 SARS-CoV-2 inoculation. For Figures 1E, F, CoV-2-infected NHBEs from 4 donors that were treated with/without 1 nM B2R antagonist 638 after 6 hours of infection for another 24 hours. Supernatants were titrated on Vero E6 cells and 639 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 plaque assay was quantified 24 hours later. Results are depicted as plaque forming units ( perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 of genes involved in the acute phase response are depicted. All entities are shown. Asterisks CoV-2 versus medium and of downregulated DEGs in SARS-CoV-2 + icatibant versus SARS-691 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101/2021.08.13.21262037 doi: medRxiv preprint CXCL8  IL6  CSF2  TNF  CCL3  IL1A  IL10  CCL2  IL6  CXCL10  CCL5  CXCL10 low high abundance All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101/2021.08.13.21262037 doi: medRxiv preprint perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted August 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Safety and Efficacy of the BNT162b2 mRNA 427

Covid-19 Vaccine

Clinical characteristics of 140 patients infected with 429 SARS-CoV-2 in Wuhan

Reduced sensitivity of SARS-CoV-2 variant 431 Delta to antibody neutralization

CoV-2 Variants

Measuring SARS-CoV-2 neutralizing 435 antibody activity using pseudotyped and chimeric viruses

Immunology of COVID-19: Mechanisms, 437 clinical outcome, diagnostics, and perspectives-A report of the European Academy of 438 Allergy and Clinical Immunology (EAACI)

Risk factors for severe and critically ill COVID-19 440 patients: A review

ARIA-EAACI statement on asthma and

Clinical characteristics of 182 pediatric COVID-19 444 patients with different severities and allergic status

SARS-CoV-2 Cell Entry Depends 446 on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Efficient 449 activation of the severe acute respiratory syndrome coronavirus spike protein by the 450 transmembrane protease TMPRSS2

Angiotensin-converting enzyme 2 is a functional 452 receptor for the SARS coronavirus

The renin-angiotensin system: An integrated view of lung disease and 454 coagulopathy in COVID-19 and therapeutic implications

The contact activation and kallikrein/kinin systems: pathophysiologic 456 and physiologic activities

Multilevel proteomics reveals host perturbations 458 by SARS-CoV-2 and SARS-CoV

Angiotensin-converting enzyme 2 protects from severe 460 acute lung failure

The ACE2/Angiotensin-(1-7)/MAS 462 Axis of the Renin-Angiotensin System: Focus on Angiotensin

Understanding the Pathophysiology of 465 COVID-19: Could the Contact System Be the Key?

Kallikrein-kinin blockade in 470 patients with COVID-19 to prevent acute respiratory distress syndrome

Bradykinin B2 receptor gene is a target of angiotensin II type 1 receptor signaling